Invited Commentary
Commentary on "Beyond PSA: Managing Modern Therapeutic Options in Metastatic Castration-Resistant Prostate Cancer"
Abstract
In this issue of the Southern Medical Journal, Karzai and colleagues1 stress the message ‘‘the use of PSA [prostatespecific antigen] criteria alone should not be used to determine the progression of disease; instead, PSA should be evaluated in combination with other clinical data.’’ This accurate statement corrects the generally perceived concept that using biochemical PSA increase is the only surrogate for CRPC [castrationresistant prostate cancer] progression. The authors provide abundant evidence from previous studies and observations regarding how PSA increases (fluctuations) correlate so poorly with the real disease severities and the success of the treatment.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Karzai FH, Madan RA, Figg WD. Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. South Med J 2015;108:224-228.
2. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed January 31, 2015.
3. American Urological Association. Castration-resistant prostate cancer. http://www.auanet.org/education/guidelines/castration-resistant-prostate-cancer.cfm. Accessed January 31, 2015.
